Wesbanco Bank Inc. Increases Stock Position in IDEAYA Biosciences, Inc. $IDYA

Wesbanco Bank Inc. boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 87.3% during the 4th quarter, Holdings Channel reports. The firm owned 39,700 shares of the company’s stock after buying an additional 18,500 shares during the quarter. Wesbanco Bank Inc.’s holdings in IDEAYA Biosciences were worth $1,372,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its position in IDEAYA Biosciences by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock worth $173,518,000 after acquiring an additional 97,116 shares in the last quarter. Baker BROS. Advisors LP raised its position in IDEAYA Biosciences by 54.6% during the third quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock valued at $89,125,000 after purchasing an additional 1,156,716 shares during the period. Fiera Capital Corp lifted its stake in shares of IDEAYA Biosciences by 20.0% in the 3rd quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock valued at $50,011,000 after purchasing an additional 305,698 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of IDEAYA Biosciences by 4.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after purchasing an additional 50,000 shares during the period. Finally, UBS Group AG increased its position in shares of IDEAYA Biosciences by 2.7% during the 4th quarter. UBS Group AG now owns 1,085,632 shares of the company’s stock valued at $37,530,000 after purchasing an additional 29,055 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

IDEAYA Biosciences stock opened at $28.32 on Friday. IDEAYA Biosciences, Inc. has a 1-year low of $16.84 and a 1-year high of $39.28. The firm has a market capitalization of $2.49 billion, a P/E ratio of -17.70 and a beta of -0.04. The company’s 50-day moving average is $32.00 and its 200 day moving average is $32.96.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. During the same quarter in the prior year, the business earned ($0.82) earnings per share. IDEAYA Biosciences’s revenue for the quarter was down 39.4% compared to the same quarter last year. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey Stein acquired 50,000 shares of IDEAYA Biosciences stock in a transaction that occurred on Monday, March 2nd. The shares were bought at an average cost of $32.96 per share, with a total value of $1,648,000.00. Following the transaction, the director directly owned 54,281 shares of the company’s stock, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 2.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IDYA shares. Guggenheim boosted their target price on IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Wells Fargo & Company boosted their target price on IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. Citigroup boosted their target price on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. The Goldman Sachs Group boosted their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, April 14th. Finally, Royal Bank Of Canada boosted their target price on IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.69.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.